TY  - JOUR
AU  - Winterer, Georg
AU  - Gallinat, Jürgen
AU  - Brinkmeyer, Jürgen
AU  - Musso, Francesco
AU  - Kornhuber, Johannes
AU  - Thuerauf, Norbert
AU  - Rujescu, Dan
AU  - Favis, Reyna
AU  - Sun, Yu
AU  - Franc, Monique A.
AU  - Ouwerkerk-Mahadevan, Sivi
AU  - Janssens, Luc
AU  - Timmers, Maarten
AU  - Streffer, Johannes R.
TI  - Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study
JO  - Neuropharmacology
VL  - 64
SN  - 0028-3908
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - FZJ-2015-04324
SP  - 197 - 204
PY  - 2013
AB  - In this multicenter, double-blind, placebo-controlled, randomized, four way cross-over proof-of-mechanism study, we tested the effect of the positive allosteric α7 nicotinic acetylcholine receptor (nAChR) modulator JNJ-39393406 in a key translational assay (sensory P50 gating) in 39 regularly smoking male patients with schizophrenia. All patients were clinically stable and JNJ-39393406 was administered as an adjunct treatment to antipsychotics. No indication was found that JNJ-39393406 has the potential to reverse basic deficits of information processing in schizophrenia (sensory P50 gating) or has a significant effect on other tested electrophysiological markers (MMN, P300 and quantitative resting EEG). Sensitivity analyses including severity of disease, baseline P50 gating, medication and gene variants of the CHRNA7 gene did not reveal any subgroups with consistent significant effects. It is discussed that potential positive effects in subgroups not present or not large enough in the current study or upon chronic dosing are possible, but unlikely to be developed.
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000311250300023
C6  - pmid:22766391
DO  - DOI:10.1016/j.neuropharm.2012.06.040
UR  - https://juser.fz-juelich.de/record/202035
ER  -